The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors
NACompletedINTERVENTIONAL
Enrollment
5
Participants
Timeline
Start Date
November 24, 2014
Primary Completion Date
September 27, 2017
Study Completion Date
November 3, 2017
Conditions
Solid Tumor
Interventions
DRUG
sirolimus
sirolimus 1mg daily
Trial Locations (1)
135-710
Samsung Medical center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02449564 - The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors | Biotech Hunter | Biotech Hunter